Saturday 17 October 2026
Export ABCL’s income statement to Excel — free account
AbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.80
0.88
−6.94%
Follow ABCL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 2 | 6 | 4 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 16.95 | 26.00 | 53.87 | 5,890.00 | 5,890.00 | — |
P/S ratio |
13.60 | 29.91 | 43.57 | 5.57 | 10.51 | 27.48 | 0.00 | 0.00 | — |
Altman Z-Score |
1.66 | 1.67 | 3.32 | 7.50 | 9.90 | 23.71 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 13.22 | 21.19 | 799.05 | 755.12 | 755.12 | — |
Altman Z″-Score (non-manufacturers) |
4.67 | 5.62 | 6.46 | 9.92 | 9.41 | 11.03 | 0.31 | — | — |
P/Operating CF |
(29.40) | (107.80) | (84.49) | 87.51 | (235.96) | 5,012.52 | (2,371.65) | (2,371.65) | — |
Beneish M-Score |
(1.06) | (2.57) | 2.55 | (3.32) | (2.71) | 17.69 | — | — | — |
P/B ratio |
1.06 | 0.82 | 1.44 | 2.19 | 3.84 | 7.71 | 1,287.81 | 1,287.81 | — |
Price to Tangible BV |
1.16 | 0.89 | 1.68 | 2.57 | 4.75 | 9.37 | 1,287.81 | 1,287.81 | — |
EV/Sales |
6.21 | 7.46 | 23.01 | 3.70 | 8.53 | 24.94 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 7.20 | 14.43 | 35.87 | 0.00 | 0.00 | — |
EV/Operating CF |
(3.55) | (1.98) | (19.94) | 6.48 | 13.08 | 256.30 | 370.33 | 370.33 | — |
EV/FCF |
(2.63) | (1.13) | (7.06) | 8.78 | 17.19 | 725.38 | 747.79 | 747.79 | — |
Quick Ratio |
9.60 | 8.93 | 6.86 | 8.03 | 7.53 | 7.80 | 1.37 | 1.83 | — |
Current Ratio |
11.32 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 | 1.60 | 2.50 | — |
Net Debt/EBITDA |
2.97 | 2.99 | 3.81 | (3.65) | (3.37) | (3.68) | 1.81 | 260.87 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.66% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.00 | — |
Asset Turnover |
0.06 | 0.02 | 0.03 | 0.34 | 0.32 | 0.45 | 0.99 | 0.00 | — |
Operating CF/Net income |
0.90 | 0.67 | 0.30 | 1.75 | 1.59 | 0.27 | (1.22) | 12.21 | — |
Capex/Depreciation |
(1.48) | (0.81) | (2.51) | (2.19) | (3.39) | (2.78) | (2.16) | (7.27) | — |
Interest Coverage |
— | — | — | 53.53 | 33.62 | 22.91 | (19.70) | (3.55) | — |
| (14.47%) | (14.75%) | (12.27%) | 14.03% | 16.53% | 20.43% | (65.94%) | 8.34% | — | |
| (10.78%) | (11.43%) | (9.67%) | 11.09% | 13.21% | 16.54% | (18.83%) | 0.00% | — | |
ROIC |
(33.25%) | (48.52%) | (40.43%) | 42.05% | 46.00% | 41.25% | (41.89%) | 0.00% | — |
Return on Tangible Assets |
(13.41%) | (16.04%) | (14.07%) | 14.10% | 16.67% | 11.69% | (16.72%) | 1.95% | — |
Average Days of Receivables |
283.21 | 425.55 | 293.63 | 29.02 | 156.21 | 333.82 | 102.97 | 41.33 | — |
Research and Development Expense of Revenue |
248.68% | 580.10% | 461.95% | 22.22% | 16.54% | 12.61% | 87.09% | 65.71% | — |
Selling, General and Administrative Expense of Revenue |
110.79% | 296.50% | 197.71% | 13.75% | 13.00% | 6.76% | 34.55% | 32.42% | — |
Intangible Assets out of Total Assets |
0.06 | 0.07 | 0.11 | 0.12 | 0.15 | 0.15 | 0.04 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
74.26% | 234.39% | 168.79% | 10.19% | 8.17% | 3.60% | 7.66% | 6.96% | — |
Graham Net Nets |
0.33 | 0.52 | 0.32 | 0.27 | 0.16 | 0.10 | 0.01 | 0.01 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 7.38 | 6.78 | 9.36 | 0.00 | 0.00 | — |
Earnings Yield |
(14.33%) | (18.77%) | (9.08%) | 5.90% | 3.85% | 1.86% | 0.02% | 0.02% | — |
Free Cash Flow Yield |
(17.34%) | (22.04%) | (7.48%) | 7.57% | 4.72% | 0.13% | 0.13% | 0.13% | — |
Revenue per Share |
0.25 | 0.10 | 0.13 | 1.70 | 1.36 | 1.46 | 0.08 | 0.06 | — |
Operating CF per Share |
(0.44) | (0.37) | (0.15) | 0.97 | 0.89 | 0.14 | 0.02 | 0.02 | — |
Capex per Share |
(0.14) | (0.27) | (0.27) | (0.25) | (0.21) | (0.09) | (0.03) | (0.04) | — |
Free Cash Flow per Share |
(0.58) | (0.64) | (0.42) | 0.72 | 0.68 | 0.05 | (0.01) | (0.01) | — |
Cash per Share |
1.87 | 2.21 | 2.72 | 3.20 | 2.71 | 3.73 | 0.05 | 0.07 | — |
Shareholders Equity per Share |
3.24 | 3.59 | 3.99 | 4.33 | 3.72 | 5.22 | 0.07 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
3.24 | 3.59 | 3.99 | 4.33 | 3.72 | 5.22 | 0.07 | 0.00 | — |
Free Cash Flow |
(174.07) | (186.95) | (121.38) | 204.70 | 186.13 | 8.02 | (1.30) | (1.74) | — |
Working Capital |
663.93 | 674.76 | 752.97 | 907.17 | 809.12 | 709.84 | 4.75 | 9.00 | — |
Capital Expenditures |
(42.77) | (78.40) | (77.51) | (72.66) | (58.45) | (14.67) | (4.00) | (5.31) | — |
Net Current Asset Value |
338.19 | 446.90 | 536.21 | 717.86 | 636.96 | 638.30 | (0.60) | 15.00 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 8.30 | 15.65 | 37.27 | 0.00 | 0.00 | — |
Capex to Sales |
0.57 | 2.72 | 2.04 | 0.15 | 0.16 | 0.06 | 0.34 | 0.60 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 12.49 | 19.29 | 41.06 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.07 | 0.28 | 0.11 | 0.15 | 0.15 | 0.29 | 0.22 | 0.12 | — |
Cash ROIC |
(11.41%) | (10.95%) | (6.26%) | 9.54% | 10.49% | 0.56% | (6.13%) | (12.44%) | — |
Accounts Receivable Turnover |
1.63 | 0.90 | 1.10 | 4.87 | 2.01 | 2.15 | 5.43 | 4.42 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
45.95 | 32.10 | 34.59 | 99.58 | 186.91 | 108.26 | 2.14 | 2.00 | — |
Average Payables |
52.89 | 52.29 | 51.04 | 42.26 | 26.11 | 11.39 | 2.29 | 2.50 | — |
Average Inventory |
— | — | — | 2.00 | — | — | — | — | — |
Average Assets |
1,358.75 | 1,424.32 | 1,514.50 | 1,429.74 | 1,162.05 | 514.51 | 11.74 | 0.00 | — |
Average Common Equity |
1,011.49 | 1,104.20 | 1,192.80 | 1,129.51 | 928.12 | 416.61 | 3.35 | 3.50 | — |
Columns are period end dates